Ovid Therapeutics Inc.

NASDAQ:OVID

Biotechnology

Healthcare
$2.26 -4.34%

-$0.11 today

Market cap
$426.53M
Beta
0.18
P/E (TTM)
-7.1
EPS (TTM)
-$0.33
52W Low $0.29High $3.11

Volume 2.16M

Average 3.07M

OVID Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Ovid Therapeutics Inc.NASDAQ: OVID

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables remains negative

Q1 FY2026 net receivables was $0, compared with $0 a year earlier.

Context

  • Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Net receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Net Receivables vs competitors

How OVID compares with its peers on the latest reported figures

  • OVID's Mar 2026 net receivables of $0 is the 6th highest of the 11 companies compared; the peer median is $822.5K.
  • Net receivables amounts to 0.0% of total assets for OVID, versus a peer median of 0.4%.
OVID Competitors Peer median
Net Receivables for OVID and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RAREUltragenyx Pharmaceutical Inc.Mar 2026$121M +22.4%+57.8%9.3%
MGTXMeiraGTx Holdings plcMar 2026$17.96M +243.7%-14.3%7.3%
ABEOAbeona Therapeutics Inc.Mar 2026$6.71M +314.9%+229.3%3.4%
STOKStoke Therapeutics, Inc.Mar 2026$6.14M +913.4%+137.8%1.4%
VYGRVoyager Therapeutics, Inc.Mar 2026$1.65M -22.0%+40.2%0.8%
OVIDOvid Therapeutics Inc.Mar 2026$0 ——0.0%
TSHATaysha Gene Therapies, Inc.Jun 2026$0 ——0.0%
WVEWave Life Sciences Ltd.Mar 2026$0 ——0.0%
NGNENeurogene Inc.Mar 2026$0 -100.0%—0.0%
RCKTRocket Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
LXEOLexeo Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
Peer median (excluding OVID) $822.5K+133.1%+57.8%0.4%

Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents187.8M44.87M27.04M26.3M13.15M
Short-term Investments084.13M78.79M26.77M56.48M
Net Receivables00000
Inventory00000
Other Current Assets2.68M11K020.81M
Total Current Assets190.48M131.38M109.6M55.94M90.45M
Property, Plant & Equipment (Net)242.76K16.07M14.66M13.23M0
Goodwill00000
Intangible Assets164K222.1K200K92K0
Long-term Investments3.56M5.62M17.63M20.97M64.7M
Tax Assets00000
Other Non-current Assets96.13K1.97M1.94M1.93M(4.22M)
Total Non-current Assets4.07M23.89M34.43M36.23M60.49M
Total Assets194.54M155.27M144.03M92.17M150.93M
Account Payables7.13M1.95M3.7M3.19M1.96M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities3.91M001K0
Total Current Liabilities14.8M6.99M11.47M10.52M8.29M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0130M00
Total Non-current Liabilities016M44.76M13.42M11.99M
Total Liabilities14.8M22.99M56.23M23.94M20.27M
Common Stock70.36K70.47K71K71K130K
Retained Earnings(171.36M)(225.53M)(277.87M)(304.3M)(321.71M)
Accumulated OCI0(42.19K)0(35K)(202K)
Other Stockholders Equity0(1)0(0)0
Minority Interest00000
Total Equity179.75M132.27M87.8M68.23M130.66M
Total Debt016.54M16M14.76M13.42M
Net Debt(187.8M)(28.33M)(11.04M)(11.55M)266K

Ovid Therapeutics Inc.

NASDAQ:OVID

Intrinsic Alpha fair value

Locked

Current Price

$2.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.